Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: A population-based prospective cohort study

Background Testicular germ cell tumor (TGCT) patients and survivors have excess mortality compared to the general male population, but relative survival (RS) has been scarcely studied. We investigated causes of excess mortality and their impact on RS among men diagnosed with TGCT in Norway, 1953–2015. Methods and findings Using registry data (n = 9541), standardized mortality ratios (SMRs) and RS were calculated. By December 31st, 2015, 816 testicular cancer (TC) and 1508 non-TC deaths had occurred (non-TC SMR: 1.36). Within five years of TGCT diagnosis, 80% were TC deaths. Non-TC second cancer (SC) caused 65% of excess non-TC deaths, of which 34% from gastric, pancreatic or bladder cancer. SC SMRs remained elevated ≥26 years of follow-up. In localized TGCT diagnosed >1979, SC SMRs were only elevated after seminoma. Cardiovascular disease caused 9% and other causes 26% of excess non-TC deaths, of which 58% from gastrointestinal and genitourinary disorders. RS continuously declined with follow-up. TGCT patients diagnosed >1989 had superior five-year TC-specific RS (98.3%), lower non-TC SMR (1.21), but elevated SMRs for several SCs, infections, Alzheimer’s disease, genitourinary disease and suicide. A limitation was lack of individual treatment data. Conclusions RS declines mainly from TC deaths <5 years after TGCT diagnosis. Later, excess SC mortality becomes particularly important, reducing RS even ≥26 years. Radiotherapy; standard adjuvant seminoma treatment 1980–2007, is likely an important contributor, as are chemotherapy and possibly innate susceptibilities. Vigilant long-term follow-up, including psychosocial aspects, is important. Further research should focus on identifying survivor risk groups and optimizing treatment.

[1]  S. Fosså,et al.  Continuing increased risk of second cancer in long‐term testicular cancer survivors after treatment in the cisplatin era , 2020, International journal of cancer.

[2]  C. Foresta,et al.  Testicular Cancer: Genes, Environment, Hormones , 2019, Front. Endocrinol..

[3]  K. Hemminki,et al.  Second cancers and causes of death in patients with testicular cancer in Sweden , 2019, PloS one.

[4]  Jongchan Kim,et al.  Recent global trends in testicular cancer incidence and mortality , 2018, Medicine.

[5]  M. Ikram,et al.  Cancer and dementia: Two sides of the same coin? , 2018, European journal of clinical investigation.

[6]  B. Mahal,et al.  Safety of combining radiotherapy with immune-checkpoint inhibition , 2018, Nature Reviews Clinical Oncology.

[7]  S. Fosså,et al.  Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors , 2018, Acta oncologica.

[8]  S. Fosså,et al.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Fosså,et al.  Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors , 2018, Advances in urology.

[10]  L. Einhorn,et al.  Long-term toxicity of cisplatin in germ-cell tumor survivors. , 2017 .

[11]  R. T. Lie,et al.  Suicide and violent deaths in survivors of cancer in childhood, adolescence and young adulthood—A national cohort study , 2017, International journal of cancer.

[12]  C. Johansen,et al.  Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. , 2016, JAMA oncology.

[13]  A. Althouse Adjust for Multiple Comparisons? It's Not That Simple. , 2016, The Annals of thoracic surgery.

[14]  M. Stockler,et al.  The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study , 2016, Journal of Cancer Survivorship.

[15]  S. Fosså,et al.  Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[16]  S. Fosså,et al.  Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Beard,et al.  Secondary malignant neoplasms in testicular cancer survivors. , 2015, Urologic oncology.

[18]  R. Bremnes,et al.  Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. , 2015, Urologic oncology.

[19]  Derick R. Peterson,et al.  Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Ming-Hui Chen,et al.  Outcomes in stage I testicular seminoma: A population‐based study of 9193 patients , 2013, Cancer.

[21]  C. Beard,et al.  Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors , 2013, Clinical genitourinary cancer.

[22]  D J Brenner,et al.  Cancer risks from diagnostic radiology: the impact of new epidemiological data. , 2012, The British journal of radiology.

[23]  P. Russo,et al.  Suicide in men with testis cancer. , 2012, European journal of cancer care.

[24]  S. Fosså,et al.  Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Janez Stare,et al.  On Estimation in Relative Survival , 2012, Biometrics.

[26]  Derick R. Peterson,et al.  Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Fosså,et al.  Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Okunieff,et al.  Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations , 2022 .

[29]  K. Hemminki,et al.  Second cancers after testicular cancer diagnosed after 1980 in Sweden. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Bjørn Møller,et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. , 2009, European journal of cancer.

[31]  A. Protheroe,et al.  Testis cancer , 2007, Postgraduate Medical Journal.

[32]  P. Hall,et al.  Noncancer causes of death in survivors of testicular cancer. , 2007, Journal of the National Cancer Institute.

[33]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[34]  A. Mykletun,et al.  Study of anxiety disorder and depression in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Andrew K. Lee,et al.  Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Fosså,et al.  Increased mortality rates in young and middle-aged patients with malignant germ cell tumours , 2004, British Journal of Cancer.

[37]  Sven Cnattingius,et al.  Mortality and cancer incidence among individuals with Down syndrome. , 2003, Archives of internal medicine.

[38]  S. Dahl [Suicide among cancer patients]. , 1991, Ugeskrift for laeger.

[39]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[40]  R. Dymock,et al.  SPERMATOCYTIC SEMINOMA , 1976, The Medical journal of Australia.

[41]  S. Rossetti,et al.  Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review. , 2018, European review for medical and pharmacological sciences.

[42]  P. Maroto,et al.  Long-term toxicity of the treatment for germ cell-cancer. A review. , 2018, Critical reviews in oncology/hematology.